Africa Corporate Wellness Market, by End User, 2018-2027
| Label | Lubiprostone | Linaclotide | Eluxadoline | Rifaximin | Alosetron | Others |
|---|---|---|---|---|---|---|
| 2015 | 384 USD Mn | 487.2 USD Mn | 368.5 USD Mn | 110 USD Mn | 59.6 USD Mn | 114.4 USD Mn |
| 2016 | 431.6 USD Mn | 542.4 USD Mn | 413.9 USD Mn | 123.6 USD Mn | 66.9 USD Mn | 128.2 USD Mn |
| 2017 | 479.6 USD Mn | 598.1 USD Mn | 459.6 USD Mn | 137.3 USD Mn | 74.2 USD Mn | 142 USD Mn |
| 2018 | 527.1 USD Mn | 653.8 USD Mn | 505 USD Mn | 151.1 USD Mn | 81.5 USD Mn | 155.8 USD Mn |
| 2019 | 573.8 USD Mn | 711.3 USD Mn | 549.8 USD Mn | 164.2 USD Mn | 88.8 USD Mn | 169 USD Mn |
| 2020 | 619.3 USD Mn | 773.8 USD Mn | 592.1 USD Mn | 177.1 USD Mn | 95.8 USD Mn | 181.5 USD Mn |
| 2021 | 664.7 USD Mn | 838 USD Mn | 634.2 USD Mn | 189.7 USD Mn | 102.6 USD Mn | 193.4 USD Mn |
| 2022 | 711.6 USD Mn | 900.1 USD Mn | 679.1 USD Mn | 202.4 USD Mn | 109 USD Mn | 204.1 USD Mn |
| 2023 | 760 USD Mn | 958.5 USD Mn | 724.4 USD Mn | 216.2 USD Mn | 115.2 USD Mn | 214.4 USD Mn |
Data Source: Wantstats Repository
Market Dynamics
linaclotide segment accounted for the largest market share in the irritable bowel syndrome treatment market, and is expected to reach USD 958.50 Million in 2023 from USD 598.10 Million in 2017.This market is projected to grow at a CAGR of 7.95% during the forecast period from 2018 - 2023.
Research Methodology
Figures reflect Wantstats’ original market research and forecasting models, compiled as part of the Wantstats research archive and published in 2023.
Unlock the Full Data
Get This Chart
Access the complete chart and underlying data to support your research, analysis, and business decisions.
Powering the world's best teams.
From next-gen startups to established enterprises.
Get in Touch
Let's work together
support@wantstats.comSee our work in action
Start your data driven journey with us!
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence



